Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP 3rd, Karlowsky JA.
Zhanel GG, et al.
Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4.
Drugs. 2020.
PMID: 31970713
Review.
Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. ...Mild, transient gastrointestinal events are the predominant adverse effects associated with use of omadacycline. Based on clinical trial data to date, the adverse effect profil …
Omadacycline is currently approved by the FDA for use in treatment of ABSSSI and CABP. ...Mild, transient gastrointestinal events are …